TY - JOUR
T1 - Design and dosimetric characterization of a transportable proton minibeam collimation system
AU - Ahmed, Mabroor
AU - Beyreuther, Elke
AU - Gantz, Sebastian
AU - Horst, Felix
AU - Meyer, Juergen
AU - Pawelke, Jörg
AU - Schmid, Thomas E.
AU - Stolz, Jessica
AU - Wilkens, Jan J.
AU - Bartzsch, Stefan
N1 - Publisher Copyright:
Copyright © 2024 Ahmed, Beyreuther, Gantz, Horst, Meyer, Pawelke, Schmid, Stolz, Wilkens and Bartzsch.
PY - 2024
Y1 - 2024
N2 - Background: Proton Minibeam Radiation Therapy has shown to widen the therapeutic window compared to conventional radiation treatment in pre-clinical studies. The underlying biological mechanisms, however, require more research. Purpose: The purpose of this study was to develop and characterize a mechanical collimation setup capable of producing 250µm wide proton minibeams with a center-to-center distance of 1000µm. Methods: To find the optimal arrangement Monte Carlo simulations were employed using the Geant4 toolkit TOPAS to maximize key parameters such as the peak-to-valley dose ratio (PVDR) and the valley dose rate. The experimental characterization of the optimized setup was carried out with film dosimetry at the University Proton Therapy beamline in Dresden and the proton beamline of the University of Washington Medical Center in Seattle with 150MeV and 50.5MeV, respectively. A microDiamond detector (PTW, Freiburg, Germany) was utilized at both beamlines for online proton minibeam dosimetry. Results: A PVDR of 10 was achieved in Dresden and a PVDR of 14 in Seattle. Dosimetry measurements were carried out with EBT3 films at a depth of 5mm in a polymethylmethacrylate (PMMA) phantom. When comparing film dosimetry with the microDiamond, excellent agreement was observed in the valleys. However, the peak dose showed a discrepancy of approximately 10% in the 150MeV beam and 20% in the 50.5MeV beam between film and microDiamond. Discussion: The characteristics of the minibeams generated with our system compares well with those of other collimated minibeams despite being smaller. The deviations of microDiamond measurements from film readings might be subject to the diamond detector responding differently in the peak and valley regions. Applying previously reported correction factors aligns the dose profile measured by the microDiamond with the profile acquired with EBT3 films in Dresden. Conclusion: The novel proton minibeam system can be operated independently of specific beamlines. It can be transported easily and hence used for inter-institutional comparative studies. The quality of the minibeams allows us to perform in vitro and in vivo experiments in the future. The microDiamond was demonstrated to have great potential for online dosimetry for proton minibeams, yet requires more research to explain the observed discrepancies.
AB - Background: Proton Minibeam Radiation Therapy has shown to widen the therapeutic window compared to conventional radiation treatment in pre-clinical studies. The underlying biological mechanisms, however, require more research. Purpose: The purpose of this study was to develop and characterize a mechanical collimation setup capable of producing 250µm wide proton minibeams with a center-to-center distance of 1000µm. Methods: To find the optimal arrangement Monte Carlo simulations were employed using the Geant4 toolkit TOPAS to maximize key parameters such as the peak-to-valley dose ratio (PVDR) and the valley dose rate. The experimental characterization of the optimized setup was carried out with film dosimetry at the University Proton Therapy beamline in Dresden and the proton beamline of the University of Washington Medical Center in Seattle with 150MeV and 50.5MeV, respectively. A microDiamond detector (PTW, Freiburg, Germany) was utilized at both beamlines for online proton minibeam dosimetry. Results: A PVDR of 10 was achieved in Dresden and a PVDR of 14 in Seattle. Dosimetry measurements were carried out with EBT3 films at a depth of 5mm in a polymethylmethacrylate (PMMA) phantom. When comparing film dosimetry with the microDiamond, excellent agreement was observed in the valleys. However, the peak dose showed a discrepancy of approximately 10% in the 150MeV beam and 20% in the 50.5MeV beam between film and microDiamond. Discussion: The characteristics of the minibeams generated with our system compares well with those of other collimated minibeams despite being smaller. The deviations of microDiamond measurements from film readings might be subject to the diamond detector responding differently in the peak and valley regions. Applying previously reported correction factors aligns the dose profile measured by the microDiamond with the profile acquired with EBT3 films in Dresden. Conclusion: The novel proton minibeam system can be operated independently of specific beamlines. It can be transported easily and hence used for inter-institutional comparative studies. The quality of the minibeams allows us to perform in vitro and in vivo experiments in the future. The microDiamond was demonstrated to have great potential for online dosimetry for proton minibeams, yet requires more research to explain the observed discrepancies.
KW - micro diamond
KW - monte carlo
KW - proton minibeam collimation
KW - proton minibeam dosimetry
KW - proton minibeam radiation therapy
KW - spatially fractionated radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85214098496&partnerID=8YFLogxK
U2 - 10.3389/fonc.2024.1473625
DO - 10.3389/fonc.2024.1473625
M3 - Article
AN - SCOPUS:85214098496
SN - 2234-943X
VL - 14
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1473625
ER -